Release details

2015-12-03 13:00 CET
  • Print
  • Share Share
en

Summit Therapeutics to Present at the 26th Annual Oppenheimer Healthcare Conference

Summit Therapeutics plc
("Summit" or the "Company")

SUMMIT THERAPEUTICS TO PRESENT AT THE 26TH ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE

Oxford, UK, 3 December 2015 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Erik Ostrowski, Summit's Chief Financial Officer, will present at the 26th Annual Oppenheimer Healthcare Conference at 10:55am EST (3:55pm GMT) on Tuesday, 8 December 2015 in New York City. 

A live audio webcast of the presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)

 
 

Tel: +44 (0)1235 443 951
   +1 617 225 4455
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson

 
 

 

Tel: +44 (0)20 77148 7900
N+1 Singer
(Broker)
Aubrey Powell / Jen Boorer 

 
 

 

Tel: +44 (0)20 7496 3000
Peckwater PR
(Financial public relations, UK)
Tarquin Edwards

 

Tel: +44 (0)7879 458 364
tarquin.edwards@peckwaterpr.co.uk
MacDougall Biomedical Communications
(US media contact)
Chris Erdman

Tel: +1 781 235 3060
cerdman@macbiocom.com
HUG#1971150